Clinical trial
Vaccine Therapy for Patients With Stage III Melanoma
NCT00052130 · CancerVax Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00052130 |
|---|---|
| Title | Vaccine Therapy for Patients With Stage III Melanoma |
| Official title | Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma |
| Lead sponsor | CancerVax Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | CancerVax vaccine (CANVAXIN) |
| Enrollment | 1,118 |
| First posted | Jan 24, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | Australia, Brazil, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Switzerland, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: